Natera (NASDAQ:NTRA – Get Rating) had its price target cut by Piper Sandler from $80.00 to $70.00 in a research note published on Monday morning, MarketBeat reports. They currently have an overweight rating on the medical research company’s stock. Piper Sandler also issued estimates for Natera’s Q1 2022 earnings at ($1.39) EPS, Q2 2022 earnings […]
Natera, Inc. (NASDAQ:NTRA – Get Rating) CEO Steven Leonard Chapman sold 1,147 shares of the business’s stock in a transaction on Thursday, March 10th. The shares were sold at an average price of $42.16, for a total transaction of $48,357.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is […]
Natera (NASDAQ:NTRA – Get Rating) had its price objective lowered by analysts at Piper Sandler from $110.00 to $80.00 in a research report issued to clients and investors on Tuesday, The Fly reports. Piper Sandler’s target price would indicate a potential upside of 26.70% from the company’s current price. A number of other brokerages also […]